Find policies, billing codes, payers, states, and providers

Acute Major Eye Infections with CC/MCC: Inpatient Reimbursement Overview

DRG 121 encompasses acute major eye infections with a Complication or Comorbidity or Major Complication or Comorbidity, including serious orbital, intraocular, and ocular surface infections requiring inpatient care. Accurate classification matters for inpatient reimbursement because complication status influences payment weight and resource allocation under Centers for Medicare & Medicaid Services rules.

Customize your policy alerts

Sign up for Acute Major Eye Infections with CC/MCC: Inpatient Reimbursement Overview policy alerts

Get alerted when relevant policies change without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

DRG 121 Overview

DRG 121 covers inpatient admissions for acute major eye infections that include a Complication or Comorbidity or a Major Complication or Comorbidity. These cases involve serious orbital, ocular surface, or intraocular infections requiring inpatient-level medical or surgical management. This Diagnosis-Related Group matters for Medicare payment because the presence of complications or major complications modifies relative resource use and impacts reimbursement under the Centers for Medicare & Medicaid Services inpatient prospective payment system.

Explore openpayer tools

View all tools

Find policies, billing codes, payers, states, and providers

Acute Major Eye Infections with CC/MCC: Inpatient Reimbursement Overview

Customize your policy alerts

Sign up for Acute Major Eye Infections with CC/MCC: Inpatient Reimbursement Overview policy alerts

Get alerted when relevant policies change without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

DRG 121 Overview

National Payment Rates

Across payers the observed rate range spans from about $370 to $39K, with the widest spread between the lowest and highest payer values shown in the table and chart below. Anthem and BCBS show the largest dispersion toward the high end while Aetna and Cigna cluster higher in median values. Refer to the table and chart below for payer-specific quartiles and medians.

The CMS 2023 data represent national Medicare fee‑for‑service inpatient payments published under the CMS Provider Utilization and Payment Data program. The table below shows average total payment, average submitted covered charges, average Medicare payment amount, and total discharges for DRG 121. Values reflect Medicare FFS payment activity at the national level for the reporting year.

Average Total Payment	Average Submitted Charges	Average Medicare Payment	Total Discharges
$15K	$52K	$12K	620

Patient Population

The DRG 121 population generally skews toward Medicare‑age beneficiaries rather than exclusively working‑age commercial members. Payer mix is therefore more weighted to Medicare fee‑for‑service, with private/commercial payers also represented but typically comprising a smaller share. This results in a mixed but Medicare‑lean demographic profile for the cases captured under this DRG.

State Payment Rates

State: Alaska1 / 49

Alaska Benchmarks

Alaska reimbursement for DRG 121 ranges from $18K to $28K across reported payers, with Blue Cross Blue Shield and Anthem clustered at $18K and Cigna at $28K. The state’s primary deviation from national averages is Cigna’s elevated mean, which exceeds typical national medians for comparable payers. See the table and chart below for payer-specific distributions.

Key Insights for Alaska

Highest payer: Cigna (mean $28K) is the highest-paying payer in Alaska; lowest payers: Blue Cross Blue Shield and Anthem (both mean $18K).
Alaska’s Cigna mean ($28K) sits well above the national medians for major payers, creating a notable upward deviation compared with national benchmarks.
The state exhibits a wide payer spread ($18K–$28K), driven primarily by Cigna’s higher mean relative to the other payers.

Clinical Trials

Acute intervention trials testing rapid topical or systemic therapies for severe bacterial, fungal, or endophthalmitis cases: these studies enroll hospitalized patients presenting with acute major eye infections requiring urgent inpatient care (often post-operative endophthalmitis, severe bacterial keratitis with sight‑threatening features, or intraocular infections). They evaluate time-to-sterilization, need for immediate surgical intervention, and early vision outcomes to determine which acute management strategies reduce progression to vision loss. This research is directly relevant to providers and payers because it targets interventions that may shorten length of stay, lower rates of emergent surgery, and reduce high-cost complications.
Comparative effectiveness studies of surgical versus medical-first management in sight-threatening intraocular infections: randomized or pragmatic cohort studies compare outcomes between patients managed primarily with urgent ophthalmic surgery (vitrectomy, drainage) versus intensive medical therapy (intraocular antibiotics, systemic antimicrobials) for defined clinical presentations. The patient population includes adults with acute endophthalmitis or severe orbital cellulitis at admission, and the studies focus on functional visual outcomes, rates of reoperation, and cumulative resource utilization. Findings inform clinicians and payers about which care pathways produce better long-term vision and lower total costs, guiding DRG-level resource allocation and care protocols.
Post-discharge outcomes and readmission prevention studies examining rehabilitation, follow-up adherence, and infection recurrence: observational cohorts or intervention trials target the transition from inpatient to outpatient care for patients treated for major eye infections, assessing factors such as outpatient topical/systemic therapy adherence, access to ophthalmology follow-up, wound healing, and rates of readmission for recurrent infection or complications. These studies often stratify by social determinants (age, comorbid diabetes, immunosuppression) to identify high-risk groups who benefit from targeted care coordination. Results are important to payers and hospital systems because reducing readmissions, preventing complications that prompt costly re-hospitalization, and optimizing post-acute care pathways can improve outcomes within this high-cost DRG.

Related Codes

113-ORBITAL-PROCEDURES-WITH-CC-MCC

Orbital Procedures with CC/MCC: Inpatient Reimbursement Overview

114-ORBITAL-PROCEDURES-WITHOUT-CC-MCC

Orbital Procedures without CC/MCC: Inpatient Reimbursement Overview

115-EXTRAOCULAR-PROCEDURES-EXCEPT-ORBIT

Extraocular Procedures Except Orbit: Inpatient Reimbursement Overview

116-INTRAOCULAR-PROCEDURES-WITH-CC-MCC

Intraocular Procedures with CC/MCC: Inpatient Reimbursement Overview

117-INTRAOCULAR-PROCEDURES-WITHOUT-CC-MCC

Intraocular Procedures without CC/MCC: Inpatient Reimbursement Overview

122-ACUTE-MAJOR-EYE-INFECTIONS-WITHOUT-CC-MCC

Acute Major Eye Infections without CC/MCC: Inpatient Reimbursement Overview

123-NEUROLOGICAL-EYE-DISORDERS

Neurological Eye Disorders: Inpatient Reimbursement Overview

124-OTHER-DISORDERS-OF-THE-EYE-WITH-MCC-OR-THROMBOLYTIC-AGENT

Other Disorders of the Eye with MCC or Thrombolytic Agent: Inpatient Reimbursement Overview

125-OTHER-DISORDERS-OF-THE-EYE-WITHOUT-MCC

Other Disorders of the Eye without MCC: Inpatient Reimbursement Overview

References

1.CPT® Codes and Descriptions. AAPC. Retrieved Jul 29, 2026.
2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Jul 29, 2026.
3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Jul 29, 2026.

Published by

Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Explore openpayer tools

View all tools

National Payment Rates

Mean Rates by Payer — National — DRG 121

Average Total Payment	Average Submitted Charges	Average Medicare Payment	Total Discharges
$15K	$52K	$12K	620

Patient Population

State Payment Rates

State: Alaska1 / 49

Alaska Benchmarks

Mean Rates by Payer — Alaska — DRG 121

Key Insights for Alaska

Highest payer: Cigna (mean $28K) is the highest-paying payer in Alaska; lowest payers: Blue Cross Blue Shield and Anthem (both mean $18K).
Alaska’s Cigna mean ($28K) sits well above the national medians for major payers, creating a notable upward deviation compared with national benchmarks.
The state exhibits a wide payer spread ($18K–$28K), driven primarily by Cigna’s higher mean relative to the other payers.

Clinical Trials

Acute intervention trials testing rapid topical or systemic therapies for severe bacterial, fungal, or endophthalmitis cases: these studies enroll hospitalized patients presenting with acute major eye infections requiring urgent inpatient care (often post-operative endophthalmitis, severe bacterial keratitis with sight‑threatening features, or intraocular infections). They evaluate time-to-sterilization, need for immediate surgical intervention, and early vision outcomes to determine which acute management strategies reduce progression to vision loss. This research is directly relevant to providers and payers because it targets interventions that may shorten length of stay, lower rates of emergent surgery, and reduce high-cost complications.
Comparative effectiveness studies of surgical versus medical-first management in sight-threatening intraocular infections: randomized or pragmatic cohort studies compare outcomes between patients managed primarily with urgent ophthalmic surgery (vitrectomy, drainage) versus intensive medical therapy (intraocular antibiotics, systemic antimicrobials) for defined clinical presentations. The patient population includes adults with acute endophthalmitis or severe orbital cellulitis at admission, and the studies focus on functional visual outcomes, rates of reoperation, and cumulative resource utilization. Findings inform clinicians and payers about which care pathways produce better long-term vision and lower total costs, guiding DRG-level resource allocation and care protocols.
Post-discharge outcomes and readmission prevention studies examining rehabilitation, follow-up adherence, and infection recurrence: observational cohorts or intervention trials target the transition from inpatient to outpatient care for patients treated for major eye infections, assessing factors such as outpatient topical/systemic therapy adherence, access to ophthalmology follow-up, wound healing, and rates of readmission for recurrent infection or complications. These studies often stratify by social determinants (age, comorbid diabetes, immunosuppression) to identify high-risk groups who benefit from targeted care coordination. Results are important to payers and hospital systems because reducing readmissions, preventing complications that prompt costly re-hospitalization, and optimizing post-acute care pathways can improve outcomes within this high-cost DRG.

Related Codes

113-ORBITAL-PROCEDURES-WITH-CC-MCC

Orbital Procedures with CC/MCC: Inpatient Reimbursement Overview

114-ORBITAL-PROCEDURES-WITHOUT-CC-MCC

Orbital Procedures without CC/MCC: Inpatient Reimbursement Overview

115-EXTRAOCULAR-PROCEDURES-EXCEPT-ORBIT

Extraocular Procedures Except Orbit: Inpatient Reimbursement Overview

116-INTRAOCULAR-PROCEDURES-WITH-CC-MCC

Intraocular Procedures with CC/MCC: Inpatient Reimbursement Overview

117-INTRAOCULAR-PROCEDURES-WITHOUT-CC-MCC

Intraocular Procedures without CC/MCC: Inpatient Reimbursement Overview

122-ACUTE-MAJOR-EYE-INFECTIONS-WITHOUT-CC-MCC

Acute Major Eye Infections without CC/MCC: Inpatient Reimbursement Overview

123-NEUROLOGICAL-EYE-DISORDERS

Neurological Eye Disorders: Inpatient Reimbursement Overview

124-OTHER-DISORDERS-OF-THE-EYE-WITH-MCC-OR-THROMBOLYTIC-AGENT

Other Disorders of the Eye with MCC or Thrombolytic Agent: Inpatient Reimbursement Overview

125-OTHER-DISORDERS-OF-THE-EYE-WITHOUT-MCC

Other Disorders of the Eye without MCC: Inpatient Reimbursement Overview

References

1.CPT® Codes and Descriptions. AAPC. Retrieved Jul 29, 2026.
2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Jul 29, 2026.
3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Jul 29, 2026.

Published by

Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

OpenPayer

Acute Major Eye Infections with CC/MCC: Inpatient Reimbursement Overview

Sign up for Acute Major Eye Infections with CC/MCC: Inpatient Reimbursement Overview policy alerts

DRG 121 Overview

Catch payer policy changes before they impact reimbursement

Catch payer policy changes before they impact reimbursement

OpenPayer

Acute Major Eye Infections with CC/MCC: Inpatient Reimbursement Overview

Sign up for Acute Major Eye Infections with CC/MCC: Inpatient Reimbursement Overview policy alerts

DRG 121 Overview

National Payment Rates

Patient Population

State Payment Rates

Alaska Benchmarks

Key Insights for Alaska

Clinical Trials

Related Codes

References

National Payment Rates

Patient Population

State Payment Rates

Alaska Benchmarks

Key Insights for Alaska

Clinical Trials

Related Codes

References